Qiagen (QGEN) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates

Core Insights - Qiagen reported revenue of $540.42 million for Q4 2025, marking a year-over-year increase of 3.7% and exceeding the Zacks Consensus Estimate by 2.36% [1] - The company's EPS for the quarter was $0.62, slightly down from $0.64 a year ago, with an EPS surprise of 0.83% [1] Financial Performance - Qiagen's stock has returned +4.9% over the past month, outperforming the Zacks S&P 500 composite's +0.9% change, and currently holds a Zacks Rank 3 (Hold) [3] - Key product sales include: - QIAstat-Dx: $39 million, exceeding the estimate of $36.66 million, with a year-over-year increase of +21.9% [4] - QuantiFERON: $123 million, slightly below the estimate of $128.51 million, with a year-over-year increase of +6% [4] - Other diagnostic solutions: $40 million, matching the estimate of $37.47 million, with no change year-over-year [4] - Other product sales: $18 million, exceeding the estimate of $15.71 million, with a year-over-year increase of +20% [4] - PCR/Nucleic acid amplification: $78 million, below the estimate of $80.01 million, with a year-over-year decrease of -4.9% [4] - Genomics/NGS: $69 million, slightly below the estimate of $70.74 million, with a year-over-year increase of +4.6% [4] - Total diagnostic solutions: $201 million, slightly below the estimate of $202.71 million, with a year-over-year increase of +2.6% [4] - Sample technologies: $175 million, exceeding the estimate of $158.35 million, with a year-over-year increase of +8% [4]